why choose us

First received: June 02, 2023

Clinical Trial: A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Atopic Dermatitis

Study Type: INTERVENTIONAL


Official Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD

Brief Summary: The primary objectives of this study are to:estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24characterize the safety and tolerability of rocatinlimab in the proposed populationevaluate the immunogenicity of rocatinlimab

Read more